BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, May 16, 2024
See today's BioWorld
Home
» Firms look to new MOAs to treat Alzheimer’s disease
To read the full story,
subscribe
or
sign in
.
Firms look to new MOAs to treat Alzheimer’s disease
March 7, 2016
By
Brian Orelli
No Comments
As Biogen Inc., Merck & Co. Inc. and Eli Lilly and Co. race to the finish line with their Alzheimer’s disease drugs that are in phase III development, two companies – Neuro-Bio Ltd. and Ironwood Pharmaceuticals Inc. – are just lacing up their shoes.
BioWorld